Indo Us Bio-Tech Ltd

Dematerialisation/rematerialisation status (quarter ended Sep 30, 2026)

• No dematerialisation/rematerialisation requests were received during the period.
• No securities were dematerialised/rematerialised; listing on stock exchanges is not applicable for this period.
• No physical certificates were mutilated or cancelled; no depository name substitution occurred.
• No exceptions, delays, or non-compliance were noted in this certificate.

AGM Details

• Date and time: 30 Sep 2026, 14:30, via VC/OAVM.

Ordinary resolutions

• Adopt audited financial statements for year ended 31 Mar 2026.
• Reappointment by rotation of Priyanka Samarth Patel.
• Appointment of statutory auditors.

Special resolutions

• Borrowing limits of the company.
• Approval of related party transactions under Section 188.

Voting results

• All resolutions deemed passed on AGM date, pending scrutineer's final report.

Dividend

• No dividend proposed or declared.

Director changes

• Priyanka Samarth Patel appointed/reappointed as director (retiring by rotation).

Auditors

• Statutory auditors appointed (details not disclosed in excerpt).

Material related party transactions

• Approval of related party transactions under Section 188.

Indo Us Bio Tech Limited: Trading window closed for Designated Persons from Oct 01, 2026 till completion of 48 hours from the announcement of the unaudited financial results for the quarter and half year ending September 30, 2026.

Financials & approval

• Board approved standalone unaudited results for quarter ended June 30, 2026; Limited Review Report attached.
• Basic EPS ₹1.51; Diluted EPS not provided.
• Auditor's review completed; no material misstatement identified.
• Board meeting held 12 Aug 2026; timings 14:30–15:10.

Financial results approved

• Unaudited standalone financial results for quarter ended 30 June 2026 approved by Board; Audit Committee reviewed.
• Statement accompanied by limited review report from auditor.
• Period: quarter ended 30 June 2026; standalone results.
• Major product segment disclosed as Seed Cultivation, Processing & Trading.
• Auditor's review indicates no material misstatement; unmodified opinion.
• Board meeting date: 12 August 2026.
• Auditor: Bhagat & Associates; Independent Auditor's Review Report under Regulation 33.

Regulatory/compliance notes

• Statement filed per SEBI LODR Regulation 33; independent limited review conducted.

Meeting Details

• Board meeting scheduled for 12 August 2026; time and venue not disclosed.

Key Agenda Items

• Unaudited financial results for the quarter ended June 30, 2026 (standalone/consolidated not specified).
• Other corporate matters.

Other Notes

• Trading window remains closed 48 hours after dissemination of unaudited standalone results for quarter ended June 30, 2026.

Committee reconstitution

• Audit Committee reconstituted: Ritaben Kikani (Chair), Shilpa Thumar, Jagdishkumar Ajudiya, Hemanshi Soni (Members).
• Nomination and Remuneration Committee: Shilpa Thumar (Chair); Ritaben Kikani; Hemanshi Soni (Members).
• Stakeholders Relationship Committee: Ritaben Kikani (Chair); Jagdishkumar Ajudiya; Hemanshi Soni; Shilpa Thumar (Members).
• Effective date of reconstitution: 21 April 2026; other disclosures remain unchanged.